Recommended

Novartis selects fourth site for US radioligand manufacturing facility
EC approves Sanofi’s Teizeild for type 1 diabetes
WEBINAR | Reflections and future opportunities in pharmaceutical microbiology
WEBINAR | Harnessing AI for more efficient clinical trials | REGISTER TODAY
Increasing the effectiveness of pharma endotoxin testing | REGISTER NOW
WEBINAR | Practical considerations for aseptic gowning in contamination control strategies
Eur. Ph. publishes new general chapter on quality of data
AbbVie licenses novel bsAb from RemeGen for $5bn
EMA and FDA issue joint AI guidance
J&J’s Caplyta demonstrates phase III promise for major depressive disorder
Harnessing digital PCR for rapid sterility testing | WEBINAR
Realising autonomous pharmaceutical operations – register now
Explore the latest issue here
Complying with USP Chapters 41 and 1251 revisions for pharma quality control | WEBINAR
news

MeiraGTx sells XLRP gene therapy to Janssen

3
SHARES

Janssen will pay up to $415 million for MeiraGTx’s botaretigene sparoparvovec, a gene therapy for treatment of X-linked retinitis pigmentosa (XLRP).

MeiraGTx sells to XLRP gene therapy to Janssen

MeiraGTx has entered into an asset purchase agreement with Janssen Pharmaceuticals for the remaining interests in botaretigene sparoparvovec (bota-vec) a gene therapy for the treatment of X-linked retinitis pigmentosa (XLRP).

 

SECURE YOUR FREE SPOT

 


This webinar to explore rapid sterility testing methods that ensure fast, reliable product release, addressing critical challenges in timely delivery and safety.

Harnessing digital PCR for rapid sterility testing | 18 March 2026 | 3PM

What you’ll discover:

  • Rapid sterility testing methods that address the challenge of lengthy testing times, improving efficiency and ensuring timely product release
  • Insights into how digital PCR technology enhances testing accuracy and sensitivity, detecting contaminants quickly and reliably
  • Real-world case studies on rapid testing implementations in the field of cell and gene therapy

A Q&A session at the end of the webinar gives the audience a chance to ask questions, such as how to implement these technologies effectively.

Register now – it’s free

Under the agreement, MeiraGTx is to receive $130 million in upfront and near-term milestone payments.

The company will receive up to an additional $285 million in cash payments upon first commercial sales of bota-vec in the US and EU, as well as for manufacturing technology transfer.

Additionally, J&J will be responsible for any royalty or milestone amounts that become payable on bota-vec to University College London.

Alexandria Forbes, PhD, president and chief executive officer of MeiraGTx said the deal puts the company in a strong financial position and allows it to increase focus on two late-stage clinical programmes in Xerostomia and Parkinson’s disease and on its manufacturing capabilities.

“In addition, we continue to expedite the development of our Riboswitch gene regulation platform prioritising targets in metabolic disease, immunology and oncology, which we believe have the potential to significantly alter outcomes in these broad disease areas,” Dr Forbes added.

Earlier this year Sanofi invested $30 million in MeiraGTx. In return it will receive a right of first negotiation for the use of MeiraGTx’s Riboswitch gene regulation technology for certain Immunology and Inflammation and CNS targets, as well as for GLP-1 and other gut peptides for metabolic disease, and for MeiraGTx’s Phase II Xerostomia programme.

About XLRP

X-linked retinitis pigmentosa is a rare genetic disease, affecting men. It manifests as impaired night vision and peripheral vision loss and can eventually lead to blindness. There are currently no effective treatments for the rare disease.

In January 2019, Janssen entered into a worldwide collaboration and licence agreement with MeiraGTx, to develop, manufacture and commercialise its inherited retinal disease portfolio, including the XLRP gene therapy.

 
Share via
Share via